2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione

Catalog No. :
ACTKPJ105
CAS No. :
50-35-1
Molecular Formula :
C13H10N2O4
Molecular Weight :
258.23

IUPAC Name:2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g99%$92.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione
IUPAC Name2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
MDL No.MFCD00153873
Molecular FormulaC13H10N2O4
Molecular Weight258.23
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O
InChI KeyUEJJHQNACJXSKW-UHFFFAOYSA-N
SynonymSedalis | Sedisperil | Synovir | Talismol | Thalidomide Celgene | UNII-4Z8R6ORS6L | .alpha.-N-Phthalylglutaramide | Algosediv | Neaufatin | Pangul | Pro-ban M | thalidomide | 3-Phthalimidoglutarimide | Imida-lab | Psychotablets | Distaxal | Imidene | Dist
CAS No.50-35-1
PubChem CID5426

Safety Data

Pictogram
Health hazardToxic
Signal Word
Danger
Hazard Statement(s)
H301-H312-H361
Precautionary Statement(s)
P201-P264-P280-P301+P310+P330-P302+P352+P312-P308+P313

Synthetic Route by SureRoute

1. ACTKPJ105 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQVBJ321 route compound structure diagram
    ACQVBJ32124666-56-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTKPJ105 route product structure diagram
    ACTKPJ10550-35-1 In Stock
Inquiry

2. ACTKPJ105 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACTKPJ105 route product structure diagram
    ACTKPJ10550-35-1 In Stock
Inquiry

Comments (0)